PhotoPharmics today announced it has been selected by MedTech Innovator as a top 50 medtech startup and will be showcased in MedTech’s 2021 cohort featuring the industry’s most transformative device, diagnostic, and digital health technologies.
“We’re delighted with this designation and honor,” said Kent Savage, CEO of PhotoPharmics. “International attention from leading organizations like MedTech brings us closer to delivering on our mission of innovation, particularly providing a breakthrough, non-invasive treatment for people suffering from the symptoms of Parkinson’s disease.”
“We’re seeing a real breakthrough here,” said Savage. “Once approved, this may be the first therapy to address non-motor problems in Parkinson’s, one that we feel promises a nearly 5-year reversal of symptom progression—based on the results of our last clinical trial.”
PhotoPharmics Innovations Address Global Health Inequalities Utah-based Life Sciences Company to...
Phase 3 Trial Aims to Establish Non-Motor Improvement in Parkinson’s PhotoPharmics and University...
FDA Grants Breakthrough Designation for Non-Invasive Phototherapy Device in Parkinson’s Disease...
As a medical device company on the edge of a major breakthrough, we get a lot of questions from people who are curious about our work and mission. We love that so many are interested in our work! We truly believe we have the technology and experience to change the world. Read more >
We wanted to take a closer look at the effects of good nutrition on people with Parkinson’s disease. And thankfully for us there was a lot of great information out there. The effects of a good diet on Parkinson’s disease is a subject that has been covered extensively by researchers, scientists and advocacy groups. Read more >
One of the things we love most about this time of year is that it allows us to start getting outside again into the warm and sunny weather. But are there any benefits to being outside for people with Parkinson’s? Read more >